Investor losses due to undisclosed product issues involving the FDA and Zoetis.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Zoetis →

  American animal health company

  Nothing else this week.

Related events

• FDA raised concerns over cell therapy evidence for Capricor Therapeutics, causing a sharp drop in stock price.Jul 27
• FDA placed a clinical hold on RGX-121 trials, leading to a sharp decline in REGENXBIO Inc.'s stock price.Sep 5